Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9245700 | 0.98 | SIGMAR1 (0.55) | SIGMAR1MAOAL3MBTL1MEN1KMT2A | |
| SCHEMBL9560040 | 0.98 | SIGMAR1 (0.55) | SIGMAR1MAOAL3MBTL1MEN1KMT2A | |
| SCHEMBL6249417 | 0.98 | SIGMAR1 (0.55) | SIGMAR1MAOAL3MBTL1MEN1KMT2A | |
| SCHEMBL430012 | 0.93 | SIGMAR1 (0.54) | SIGMAR1MAOAL3MBTL1MEN1KMT2A | |
| SCHEMBL184329 | 0.83 | GPR52 (0.48) | SIGMAR1MEN1KMT2A | |
| SCHEMBL27820823 | 0.83 | MEN1 (0.51) | SIGMAR1L3MBTL1MEN1KMT2A | |
| SCHEMBL5852908 | 0.83 | TRPV1 (0.50) | SIGMAR1MAOAL3MBTL1MEN1KMT2A | |
| SCHEMBL5852915 | 0.83 | TRPV1 (0.50) | SIGMAR1MAOAL3MBTL1MEN1KMT2A | |
| SCHEMBL27303810 | 0.81 | GPR52 (0.47) | SIGMAR1MEN1KMT2A | |
| SCHEMBL5853432 | 0.81 | TRPV1 (0.53) | SIGMAR1MAOAL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5563143-A | ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISORDERS | PFIZER INC. (US) | 1996-10-08 | — | — | US | claimed |
| EP-0706795-A2 | Catechol diether compounds as inhibitors of TNF release | PFIZER INC. (US) | 1996-04-17 | — | — | EP | claimed |
| CN-113906027-A | Phenethyl substituted imidazo [4,5-c ] quinoline compounds with N-1 branched groups | 3M创新有限公司 | 2022-01-07 | — | — | CN | disclosed |
| WO-2021107870-A1 | ANTIMICROBIAL AGENT, COATING FORMULATION, COMPOSITE SURFACE COATING AND METHODS OF PREPARING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-06-03 | — | — | WO | disclosed |
| US-9802902-B2 | Antifungal compound | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-10-31 | — | — | US | disclosed |
| US-20170037013-A1 | ANTIFUNGAL COMPOUND | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-02-09 | — | — | US | disclosed |
| US-9493424-B2 | Antifungal compound | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-15 | — | — | US | disclosed |
| US-20150203454-A1 | ANTIFUNGAL COMPOUND | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-23 | — | — | US | disclosed |
| WO-2014025314-A1 | An Antifungal Compound | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-02-13 | — | — | WO | disclosed |
| EP-2226632-B1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8450070-B2 | Method for screening of cell-protecting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-0458207-A2 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-27 | — | — | EP | disclosed |
| EP-0256982-B1 | METHOD FOR THE PREPARATION OF OPTICALLY ACTIVE SECONDARY ARYL AMINES | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
| EP-0419409-A2 | Iridium complexes, process for their preparation and their use | CIBA-GEIGY AG (CH) | 1991-03-27 | — | — | EP | disclosed |
| CN-1049664-A | Optically active 4-hydroxyl-8-(3-low-alkoxy-4-phenyl sulfinyl phenyl) pyrazolo [1,5-α]-1,3,5-triazines salt and method for making thereof | OTSUKA PHARMA CO LTD (JP) | 1991-03-06 | — | — | CN | disclosed |
| EP-0414200-A2 | Salts of optically active 4-hydroxy-8-(3-lower alkoxy-4-phenylsulfinylphenyl)pyrazolo [1,5-a]-1,3,5-triazines and a process for production thereof | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1991-02-27 | — | — | EP | disclosed |
| US-4994615-A | Hydrogenation of prochiral N-arylketimines using iridium catalyst | CIBA-GEIGY CORPORATION (US) | 1991-02-19 | — | — | US | disclosed |
| US-4990232-A | Photooxidation of N,N*-substituted thiourea | CIBA-GEIGY CORPORATION (US) | 1991-02-05 | — | — | US | disclosed |
| EP-0307361-A2 | Process for the preparation of carbodiimides | CIBA-GEIGY AG (CH) | 1989-03-15 | — | — | EP | disclosed |
| EP-0301457-A2 | Process for the preparation of optically active secondary amines | CIBA-GEIGY AG (CH) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203454-A1 | ANTIFUNGAL COMPOUND | ERG28, DPM1, BAK1 | SIGMAR1 4346/4885MAOA 528/4885L3MBTL1 2477/4885 |
| US-20170037013-A1 | ANTIFUNGAL COMPOUND | ERG28, DPM1, BAK1 | SIGMAR1 4346/4885MAOA 528/4885L3MBTL1 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.